Who is sponsoring NCT00577096?

NCT00577096 is sponsored by University of Arkansas.

What condition does NCT00577096 study?

NCT00577096 studies Multiple Myeloma.

What drugs are being tested in NCT00577096?

Interventions: Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Epoetin Alfa, Total Therapy II, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan.

What is the status of NCT00577096?

NCT00577096 is currently COMPLETED.

Last reviewed 2015-04-02 · How we verify

Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

NCT00577096 NA COMPLETED Results posted

The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training for patients being treated with high-dose chemotherapy and autologous peripheral bloodstem cell transplantation (PBSC T) for multiple myeloma. The endpoints for the study included the number of attempts at and total number of days of stem cell collection, number of RBC and platelet transfusions during the transplantation period, time-to-recovery after transplantation, and response to intensive therapy for multiple myeloma.

Details

Lead sponsor	University of Arkansas
Phase	NA
Status	COMPLETED
Enrolment	120
Start date	2001-10
Completion	2004-06

Conditions

Multiple Myeloma

Interventions

Epoetin Alfa
Exercise
Autologous Peripheral Blood Stem Cell Transplantation
Red Blood Cell Transfusion
Thalidomide
Heparin, Low-Molecular-Weight
Platelet Transfusion
Melphalan
Epoetin Alfa
Total Therapy II

Primary outcomes

Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term) — up to 15 weeks
The targeted hemoglobin level for each participant was 10-12 g/dl. This is the number of red blood cell (RBC) transfusions administered to participants, as part of the investigational therapy algorithm, in an attempt to alleviate the anemia caused by multiple myeloma and high-dose chemotherapy. The numbers of RBC and platelet transfusions were obtained from the University of Arkansas for Medical Sciences blood bank.
Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term) — up to 30 weeks
The targeted hemoglobin level for each participant was 10-12 g/dl. This is the number of red blood cell (RBC) transfusions administered to participants, as part of the investigational therapy algorithm, in an attempt to alleviate the anemia caused by multiple myeloma and high-dose chemotherapy. The numbers of RBC and platelet transfusions were obtained from the University of Arkansas for Medical Sciences blood bank.
Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term) — up to 15 weeks
Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term) — up to 30 weeks
Number of Stem Cell Collection Attempts (Short Term) — up to 15 weeks
Number of Stem Cell Collection Attempts (Long Term) — up to 30 weeks

Countries

United States